Search information pages
About Cardiovascular Diabetology
This page includes information about the aims and scope of Cardiovascular Diabetology, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.
Aims & scope
Cardiovascular Diabetology considers manuscripts on all aspects of the diabetes/cardiovascular interrelationship and the dysmetabolic syndrome; this includes genetic, experimental, clinical, pharmacological, epidemiological, molecular biology and laboratory research.
Cardiovascular Diabetology aims to provide a home for all types of scientific communications related to the diabetes/cardiovascular interrelationship and the dysmetabolic syndrome. The impressive correlation between coronary artery disease and alterations in glucose metabolism has raised the likelihood that atherosclerosis and type 2 diabetes may share common antecedents. Large-vessel atherosclerosis can precede the development of diabetes, suggesting that rather than atherosclerosis being a complication of diabetes, both conditions may share genetic and environmental antecedents, a "common soil". Insulin resistance and hyperinsulinemia lead to the development of the dysmetabolic syndrome, consisting of abdominal obesity, impaired fasting glucose, high triglyceride levels, low high-density lipoprotein levels and hypertension. Taking into consideration that this cluster of abnormalities is shared by both diabetes type 2 and atherosclerosis, the American Heart Association stated in 1999 that "diabetes is a cardiovascular disease".
The worldwide prevalence of the dysmetabolic syndrome and diabetes mellitus - especially type 2, which makes up about 90% of the diabetic population - has continuously and rapidly increased over the last decades. The number of diabetic individuals is to double within 30 years, reaching 300 million in the year 2025. Premature atherosclerosis contributes to 75% of deaths among individuals with both type 1 and type 2 diabetes. Moreover, 25% of patients with newly diagnosed type 2 diabetes already have coronary artery disease. Diabetes mellitus has become a diagnosis of considerable and ominous importance in cardiovascular medicine, related to numerous hospital readmissions and high mortality and morbidity. Despite considerable improvements in the treatment of cardiovascular diseases, there is alarming evidence that patients with diabetes have hardly experienced any advantages from recent therapeutic achievements compared with their non-diabetic counterparts. As such, Cardiovascular Diabetology is an essential publication specifically dedicated to these issues.
All articles published by Cardiovascular Diabetology are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
Authors of articles published in Cardiovascular Diabetology are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.
For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Cardiovascular Diabetology therefore levies an article-processing charge of £1415/$2215/€1805 for each article accepted for publication. If the submitting author's institution is a Member, the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
All articles published in Cardiovascular Diabetology are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in Cardiovascular Diabetology include:
- Current contents
- Google Scholar
- PubMed Central
- Science Citation Index Expanded
The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives including e-Depot (The Netherlands).
The full text of all research articles published by BioMed Central is also available on SpringerLink.
Cardiovascular Diabetology is tracked by Thomson Reuters (ISI) and has an Impact Factor of 4.02.
Publication and peer review process
Criteria for publication
Cardiovascular Diabetology considers the following types of articles:
Original investigations: reports on previously unpublished data with clear experimental or clinical relevance.
Reviews: summaries of recent insights in specific research areas within the scope of Cardiovascular Diabetology. These articles should address a particular question or issue and provide an evidence-based and balanced approach on the focused topic. The reviews should include the description of how the relevant evidences were identified, assessed for quality, and selected for inclusion. Controversial aspects and unresolved issues should be discussed. Authors should justify in the cover letter their expertise in the target area, and also both the scientific relevance and the lack of recent reviews on the topic.
Case reports: articles that 1. can be used for educational purposes, as a necessary reminder of an important clinical lesson, or that describe a diagnostic or therapeutic dilemma; 2. suggest the need for change in practice or thinking in terms of diagnosis or prognosis, but not in terms of preventive or therapeutic intervention, which require stronger evidence; 3. suggest an association between two conditions; or 4. present an important adverse reaction to treatment.
Commentaries: short, narrowly focused articles of contemporary interest, usually commissioned by the journal. They are not minireviews. A Commentary is usually a discussion of an article or trial that was recently published or that is soon to be published, and that is interesting enough to warrant further comment or explanation. This type of Commentary discusses specific issues within a subject area rather than the whole field, explains the implications of the article and put it in context. Opinions are welcome as long as they are factually based.
Hypotheses: reports presenting an untested original hypothesis backed up solely by a survey of previously published results rather than any new evidence. Hypotheses should not be reviews and should not contain new data. They should ideally be short articles (maximum 1500 words) outlining significant progress in thinking that would also be testable, though not so easily testable that readers will wonder why the testing has not already been done.
Methodology articles: reports presenting a new experimental method, test or procedure. The method described may either be completely new, or may offer a better version of an existing method. The article must describe a demonstrable advance on what is currently available. The method needs to have been well tested and ideally, but not necessarily, used in a way that proves its value.
Study protocols: describe proposed or ongoing research, providing a detailed account of the hypothesis, rationale, and methodology of the study. Authors of protocols or reports of controlled trials of health care interventions must register their trial prior to submission in a suitable publicly accessible registry.
Peer review in Cardiovascular Diabetology is designed to ensure that the research published is 'good science'. The journal considers manuscripts spanning a wide range of scientific interests, as long as the results and conclusions are scientifically justified and not misleading. In deciding whether to accept or reject a manuscript, a reviewer asks him/herself whether the scientific community is better served by publishing or not publishing the manuscript. The suitability of a research article for publication in the journal is assessed by peer reviewers, who base their decision primarily on the article's validity and coherence but who also consider its comprehensibility and level of interest to the reader.
Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Cardiovascular Diabetology, a personalized section of the site.
High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.
Cardiovascular Diabetology will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.
All manuscripts submitted to Cardiovascular Diabetology should adhere to BioMed Central's editorial policies.
Citing articles in Cardiovascular Diabetology
Articles in Cardiovascular Diabetology should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Cardiovasc Diabetol [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Cardiovasc Diabetol 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Why publish your article in Cardiovascular Diabetology?
Cardiovascular Diabetology's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.
Speed of publication
Cardiovascular Diabetology offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be available through Cardiovascular Diabetology, BioMed Central and PubMed Central and will also be included in PubMed.
Online publication in Cardiovascular Diabetology gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Cardiovascular Diabetology are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Cardiovascular Diabetology's pages and on the BioMed Central homepage.
In addition, articles published in Cardiovascular Diabetology may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Cardiovascular Diabetology. A list of articles recently press-released by journals published by BioMed Central is available here.
Authors of articles published in Cardiovascular Diabetology retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright policy and license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.